TCI Wealth Advisors Inc. lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,070 shares of the company's stock after acquiring an additional 3,096 shares during the quarter. Johnson & Johnson accounts for 0.5% of TCI Wealth Advisors Inc.'s portfolio, making the stock its 25th largest position. TCI Wealth Advisors Inc.'s holdings in Johnson & Johnson were worth $6,811,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Lantz Financial LLC lifted its holdings in shares of Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after acquiring an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $453,000. Horan Securities Inc. lifted its holdings in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after buying an additional 90 shares in the last quarter. Strategic Financial Concepts LLC lifted its holdings in Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after buying an additional 1,271 shares in the last quarter. Finally, State of Wyoming lifted its holdings in Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after buying an additional 10,279 shares in the last quarter. Institutional investors own 69.55% of the company's stock.
Analysts Set New Price Targets
JNJ has been the subject of a number of research analyst reports. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday. Barclays decreased their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Royal Bank Of Canada reiterated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Finally, Bank of America decreased their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $170.88.
Get Our Latest Analysis on JNJ
Johnson & Johnson Stock Down 0.6%
Shares of NYSE JNJ traded down $0.92 during trading hours on Friday, hitting $149.81. 22,591,152 shares of the stock were exchanged, compared to its average volume of 7,993,824. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a market cap of $360.44 billion, a PE ratio of 16.66, a PEG ratio of 2.27 and a beta of 0.42. The firm has a fifty day moving average price of $154.07 and a 200-day moving average price of $153.68. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.47%. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
